Protara Therapeutics Announces Positive Interim Results Demonstrating Durable Responses in the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC
April 26, 2025 10:00 ET | Source: Protara Therapeutics TARA-002 demonstrates 100%…
UNITY Biotechnology, Inc. Reports First Quarter 2025 Financial Results and Business Updates
SOUTH SAN FRANCISCO, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- UNITY Biotechnology,…
Oculis and EURETINA Announce the 2025 Ramin Tadayoni Award
ZUG, Switzerland, April 17, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq:…
Protara Therapeutics to Present Interim Analysis from the Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC at the American Urological Association Annual Meeting
April 10, 2025 16:05 ET | Source: Protara Therapeutics NEW YORK, April…
Seegene Announces Development of CURECA, a Next-Generation Fully Automated PCR Solution Featuring Customizable Pre-treatment Automation
- Seegene to showcase a conceptual video introducing CURECA™ at ESCMID Global 2025 —…
ABL Bio Announces Grabody-B Brain Delivery Platform License Agreement with GSK to Develop Novel Medicines for Neurodegenerative Diseases
- ABL Bio and GSK enter into a multi-program agreement to develop…
Rhythm Pharmaceuticals to Announce Topline Results from Pivotal Phase 3 TRANSCEND Trial Evaluating Setmelanotide in Patients withAcquired Hypothalamic Obesity
Company to host conference call on April 7 at 8 a.m. ET…
Mesoblast Allogeneic Cell Therapy Products Are Designated U.S. Country of Origin and Not Subject to U.S. Tariffs
April 03, 2025 18:58 ET | Source: Mesoblast Limited NEW YORK, April…
VectorY Therapeutics Appoints Olga Uspenskaya-Cadoz as Chief Medical Officer
~ Appointment Strengthens Clinical Leadership as VectorY Prepares to Submit Investigational New…
Atea Pharmaceuticals Highlights Actions Underway to Enhance Shareholder Value
March 26, 2025 13:58 ET | Source: Atea Pharmaceuticals, Inc. BOSTON, March…